View Older Stories View More Recent Stories
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT), Says DM1 Data Could Move Stock
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
BMO Capital Highlights Favorite Names for 2025 in Biotech
-
RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
-
RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
-
Sarepta Therapeutics (SRPT) PT Lowered to $75 at H.C. Wainwright
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Lowered to $182 at Piper Sandler
-
Sarepta Therapeutics (SRPT) PT Lowered to $202 at Needham
-
Morgan Stanley Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT) on Arrowhead (ARWR) deal
-
Arrowhead Pharmaceuticals (ARWR) Climbs 32% Following Pact with Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals (ARWR) for Multiple Clinical and Preclinical siRNA Programs
-
Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Lowered to $193 at Baird
-
Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT) to Overweight
-
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 68c
-
Jefferies Starts Sarepta Therapeutics (SRPT) at Buy
-
Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Raymond James Resumes Sarepta Therapeutics (SRPT) at Outperform
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
BMO on Sarepta (SRPT): 'Long-Term Elevidys Data Support Uptake & Competitive Positioning'
-
RBC makes changes to its Top 30 Global Ideas for 2024
-
TD Cowen Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) Appoints Deirdre Connelly to its Board
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
TD Cowen Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
Evercore ISI Upgrades Sarepta Therapeutics (SRPT) to Outperform
-
Sarepta Therapeutics (SRPT) PT Lowered to $200 at Piper Sandler
-
Sarepta Therapeutics (SRPT) PT Lowered to $181 at RBC Capital
-
Sarepta Therapeutics (SRPT) Tops Q2 EPS by 57c, provides guidance
-
Eight defensive growth stocks to own right now
-
RBC Capital Upgrades Sarepta Therapeutics (SRPT) to Outperform
-
Cassava Sciences (SAVA): Remi Barbier resigns as President and CEO and from the Board of Directors
-
2Q24 U.S. biotech earnings preview
-
Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Citi Downgrades Sarepta Therapeutics (SRPT) to Neutral
-
Baird on Sarepta (SRPT): 'we think the regulatory progress can generate incremental optimism around the valuation'
-
Sarepta Therapeutics (SRPT) call put ratio 2 calls to 1 put with focus on August 175 and 195 calls
-
Sarepta Therapeutics (SRPT) PT Raised to $200 at Mizuho
-
Sarepta Therapeutics (SRPT) option active with focus on August 175 calls as share price up 36%
-
Sarepta Therapeutics (SRPT) PT Raised to $203 at TD Cowen
-
Sarepta Therapeutics (SRPT) call put ratio 2.9 calls to 1 put as share price up 38% after expanded FDA approval of Elevidys for DMD
-
Sarepta Therapeutics (SRPT) call put ratio 2.4 calls to 1 put into expanded FDA approval of Elevidys for DMD
-
Citi Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Raised to $200 at Baird, 'Best Case Label'
